Johnson & Johnson tops forecasts
The results surpassed Wall Street expectations.
The world’s biggest maker of healthcare products posted revenue of $US18.48 billion in the period, topping Street forecasts. Five analysts surveyed by Zacks Investment Research expected $US17.89 billion.
Johnson & Johnson shares have increased 20 per cent since the beginning of the year, while the Standard & Poor’s 500 index has increased 6 per cent. The stock has risen 22 per cent in the last 12 months.